Core Viewpoint - Aethlon Medical, Inc. is set to present at the Emerging Growth Conference on February 25, 2026, highlighting its focus on developing medical products for cancer and life-threatening infectious diseases [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, specializing in the development of the Hemopurifier, which targets pathogenic substances in biological fluids [1] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, addressing unmet needs in oncology and infectious diseases [1] Product Details - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses [1] - The device operates extracorporeally with a blood pump, utilizing plasma separation, size exclusion, and affinity binding to target mannose-rich surfaces on EVs and viruses [1] Conference Information - The Emerging Growth Conference provides a platform for public companies to present their innovations and engage with investors, featuring a live interactive format [1] - Aethlon's CEO and CFO will participate in a fireside chat and answer questions from attendees, with an archived webcast available for those unable to attend live [1]

Group 1 - The annual meeting of Aethlon Medical, Inc. was held virtually on February 19, 2026, at 8:00 a.m. Pacific Time, allowing shareholders to participate conveniently regardless of their location [1] - The meeting was led by Jim Frakes, who serves as both CEO and CFO of the company [1] - The Board members present included Edward G. Broenniman, Dr. Chetan Shah, Angela Rossetti, and Nicolas Gikakis, along with Michele Bombardiere, the VP Controller [2] Group 2 - Jennifer Trowbridge from Procopio, Cory, Hargreaves & Savitch LLP was introduced as the outside legal counsel and served as the Inspector of Election and Secretary of the Annual Meeting [2]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - Operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two patients treated in the second cohort [7][29] - The R&D team is exploring the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with Trialfacts and Dedicated [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company aims to advance the Hemopurifier platform while managing costs effectively [5] - The focus remains on the Australian oncology trial, with no plans to expand to other markets like India at this time [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the oncology trial and the potential for the Hemopurifier to serve multiple indications [11][29] - The company is committed to maintaining cost containment while advancing its research and development efforts [27] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal [10] - The next earnings call for fiscal Q4, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [18][19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive treatment method, making it easier for both hospital staff and patients [20][23] Question: Cost-effective approach in R&D - The company is focused on keeping costs down while advancing research, utilizing in-house resources as much as possible [26][27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is essential to investigate Cohort 3 to determine if three treatments could yield better results than two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before integration [46][47] Question: Future trials in India - The company is currently focused on the Australian trial and does not plan to return to India for additional trials [75][81]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two Hemopurifier treatments completed in the second cohort [7][9] - The R&D team is exploring the compatibility of the Hemopurifier with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for advertising and pre-screening [8] - The study is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its potential as a multi-indication therapeutic [5] - The integration of the Hemopurifier with the SLAMB system could facilitate its use in oncology units and infusion centers, reducing invasiveness for patients [23][24] - The company aims to build on preclinical data in Long COVID and explore other indications related to extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of cost containment while advancing clinical trials and R&D efforts [27] - The company is currently focused on completing the Australian trial and is not planning to expand to other regions like India at this time [75][78] Other Important Information - The next earnings call for the fiscal fourth quarter, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive catheter insertion, making it easier for patients and hospital staff to administer treatments [24] Question: Cost-effective approach in R&D - The company is trying to keep costs down by conducting work in-house and limiting outside lab involvement while still advancing research [27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is important to investigate the third cohort to assess the potential benefits of three treatments compared to two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before using it with the Hemopurifier [47]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [14] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control, with ongoing enrollment in the Australian oncology trial [5] - The second cohort of the oncology trial has seen two patients treated with Hemopurifier, with a third patient expected to be treated by the end of February [6][7] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for recruitment [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [5][10] - Aethlon Medical is also exploring the potential of the Hemopurifier in treating conditions beyond oncology, including Long COVID and other diseases associated with extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the Australian oncology trial and the potential for the Hemopurifier to be integrated into oncology units and infusion centers, reducing invasiveness for patients [22][24] - The company is committed to cost containment while advancing its research and development efforts, particularly in the context of Long COVID [26] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal, indicating the company's commitment to transparency and scientific rigor [10] - The next earnings call for the fiscal fourth quarter is scheduled to coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - Management confirmed that participants in Cohort 2 will receive two Hemopurifier treatments, maintaining the same follow-up period as Cohort 1 [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system is expected to simplify the administration of Hemopurifier treatments, making it less invasive for patients and easier for hospital staff [22][24] Question: Cost-effective approach in R&D - Management emphasized the importance of cost containment while advancing research, focusing on in-house work and limiting external lab involvement [26] Question: Timeline for Data Safety Monitoring Board's decision - Management anticipates a decision from the Data Safety Monitoring Board on whether to advance to the third cohort on the same day or the next business day after the meeting [34] Question: Need for Cohort 3 - Management believes it is essential to conduct Cohort 3 to fully assess the efficacy of three treatments, based on historical data suggesting that more treatments may yield better results [60] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company will need to conduct safety tests and treatments before integration with the Hemopurifier [45]

Financial Performance - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2,062,000, an increase of $247,000 or 13.6% compared to $1,815,000 for the same period in 2024[113]. - The net loss for the three months ended December 31, 2025, increased to approximately $2,018,000 from approximately $1,755,000 in the same period of 2024, with a basic and diluted loss attributable to common stockholders of ($2.45) compared to ($10.05) in 2024[118]. - For the nine months ended December 31, 2025, consolidated operating expenses were approximately $5,364,000, a decrease of $1,973,000 or 26.9% compared to $7,337,000 for the same period in 2024[119]. - The net loss for the nine months ended December 31, 2025, improved to approximately $5,267,203 from approximately $7,133,000 in 2024, with a basic and diluted loss attributable to common stockholders of ($11.01) compared to ($48.35) in 2024[123]. Cash Flow and Working Capital - As of December 31, 2025, the company had a cash balance of $6,956,397 and working capital of $5,884,382, compared to a cash balance of $5,501,261 and working capital of $4,050,514 at March 31, 2025[124]. - The company used approximately $5,250,000 in operating activities for the nine months ended December 31, 2025, compared to approximately $5,973,000 for the same period in 2024, reflecting an improvement of approximately $723,000[127]. - During the nine months ended December 31, 2025, the company raised approximately $6,728,000 through financing activities, an increase of approximately $1,350,000 compared to $5,368,000 for the same period in the prior year[128]. Product Development and Clinical Trials - The Hemopurifier has been designated as a "Breakthrough Device" by the FDA for two independent indications, with ongoing clinical trials in Australia for patients with solid tumors[99][100]. - The company has sufficient inventory of Hemopurifiers to support ongoing trials and is awaiting FDA approval for manufacturing at its San Diego facility[108]. - The company continues to explore new applications for the Hemopurifier through pre-clinical research and collaborations, demonstrating over 98% removal of disease-relevant extracellular vesicles in studies[105]. - Clinical trial expenses for the planned oncology trial in Australia are expected to increase, including costs for manufacturing additional Hemopurifiers[129]. Future Outlook and Risks - Future capital requirements will depend on various factors, with expectations of continued negative cash flows and net losses for the foreseeable future[130]. - The company plans to access equity markets for additional capital, but there is no assurance of favorable terms[131]. - Potential worsening global economic conditions may adversely impact the ability to raise additional funds[132]. Accounting Estimates - Critical accounting estimates include long-lived assets, stock-based compensation, and clinical trial accruals, which are essential for portraying financial condition[134].

Financial Performance - Aethlon Medical reported a cash balance of approximately $7.0 million as of December 31, 2025[9]. - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% from $1.81 million in the same period in 2024[10]. - Operating expenses for the nine months ended December 31, 2025, decreased by approximately $1.98 million or 26.9%, totaling approximately $5.36 million compared to $7.34 million for the same period in 2024[12]. - Other income, primarily interest income, totaled $44,000 for the three months ended December 31, 2025, compared to $60,000 in the prior-year period[11]. - Net loss for the three months ended 12/31/25 was $2,018,245, compared to a net loss of $1,754,783 for the same period in 2024, indicating an increase of 15.1%[26]. - Net loss for the nine months ended 12/31/25 was $5,267,203, a decrease of 26.1% compared to $7,133,196 for the same period in 2024[26]. - Comprehensive loss for the three months ended 12/31/25 was $2,021,705, compared to $1,767,840 for the same period in 2024, representing a 14.4% increase[26]. Cost Management - The company maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to the prior year[5]. - Total operating expenses for the three months ended 12/31/25 were $2,062,116, an increase from $1,814,747 for the same period in 2024, representing a 13.6% rise[26]. - Total operating expenses for the nine months ended 12/31/25 were $5,364,335, down 26.9% from $7,337,402 for the same period in 2024[26]. - Payroll and related expenses for the three months ended 12/31/25 were $987,424, an increase of 59.1% from $620,487 in the same period last year[26]. - General and administrative expenses for the three months ended 12/31/25 were $741,650, a decrease of 9.2% from $816,383 for the same period in 2024[26]. Clinical Development - Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial is actively underway, building on favorable results from Cohort 1[4]. - The Hemopurifier is being evaluated for compatibility with a simplified blood treatment system, potentially broadening its clinical application[5]. - Aethlon's preclinical Long COVID research demonstrated that the GNA affinity resin binds EVs from patient samples, supporting the Hemopurifier's potential as a multi-indication therapeutic approach[6]. - The company continues to advance its clinical programs and research initiatives with operational discipline, aiming to deliver therapeutic solutions for cancer and life-threatening infectious diseases[9]. Shareholder Information - Basic and diluted loss per share attributable to common stockholders for the three months ended 12/31/25 was $2.45, a significant improvement from $10.05 in the same period last year[26]. - Weighted average number of common shares outstanding for the three months ended 12/31/25 was 823,126, significantly higher than 174,529 for the same period in 2024[26]. Asset Management - The total assets of Aethlon Medical as of December 31, 2025, were approximately $8.06 million, an increase from $7.36 million as of March 31, 2025[24].

Core Insights - Aethlon Medical reported its fiscal Q3 2026 financial results, highlighting advancements in clinical and research programs, operational efficiencies, and ongoing technology development [1] Financial Performance - As of December 31, 2025, Aethlon had a cash balance of approximately $7.0 million [1] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% from $1.81 million in Q3 2025, primarily due to higher payroll costs [1] - For the nine months ended December 31, 2025, consolidated operating expenses were approximately $5.36 million, a decrease of approximately $1.98 million or 26.9% compared to $7.34 million in the same period in 2024 [1] Operational Efficiency - The company maintained disciplined cost controls, resulting in a 26.9% decline in operating expenses year-to-date compared to the prior year [1] - Aethlon is actively progressing in its Australian oncology trial, with Cohort 2 enrollment and treatment underway, building on favorable results from Cohort 1 [1] Technology Development - Aethlon is evaluating the Hemopurifier® compatibility with a simplified blood treatment system under a Material Transfer Agreement, which may enhance its use in oncology units [1] - The company continues to advance its preclinical extracellular vesicle (EV) research platform, with recent findings on Long COVID published and submitted for peer review [1] Scientific Advancement - The R&D team is exploring the potential of the Hemopurifier to remove various EVs implicated in diseases beyond cancer, including Lupus and Cardiovascular Diseases [1] - Aethlon's research indicates that the Hemopurifier may serve as a "pipeline within a single device" for multiple therapeutic applications [1] Clinical Progress - The ongoing Australian oncology trial aims to evaluate the safety and feasibility of Hemopurifier treatments in patients with solid tumors [1] - The trial is designed to assess appropriate dosing in participants receiving anti-PD-1 agents [1] Nasdaq Compliance - Aethlon has maintained compliance with Nasdaq listing requirements, resolving all prior compliance matters [1]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal third quarter ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call on February 12, 2026, at 4:30 p.m. ET, which will include a question and answer session [2] - Interested parties can register for the conference call online, and registered participants will receive a dial-in number [2] Group 2: Conference Call Access - For those without internet access, a toll-free number is available for participation in the conference call [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until March 12, 2026 [4] Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may have applications in cancer treatment [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

As filed with the Securities and Exchange Commission on January 7, 2026. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 AETHLON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sorr ...